Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant increase in its stock price, with a year-to-date rise exceeding 1500% as of the latest report, reflecting strong market interest and investor confidence [1] Group 1: Stock Performance - Beihai Kangcheng-B's stock price rose nearly 17%, reaching HKD 2.23, with a trading volume of HKD 41.075 million [1] - The cumulative increase in stock price for the year has surpassed 1500% [1] Group 2: Strategic Partnerships - Beihai Kangcheng has entered into a share subscription agreement with Baiyang Pharmaceutical, where Baiyang will subscribe for shares valued at approximately HKD 100 million at a price of HKD 1.34 per share [1] - The companies have also signed an exclusive commercialization service agreement, enhancing their strategic collaboration [1] Group 3: Product Development and Regulatory Approval - Three rare disease products from Beihai Kangcheng have passed the preliminary review for the commercial insurance innovative drug directory announced by the National Healthcare Security Administration [1] - The products include: - Goryenin (injectable velaglucerase beta) for long-term enzyme replacement therapy for patients aged 12 and above with Type I and III Gaucher disease, approved for market in May [1] - Mairuibai (oral chloramphenicol) for treating cholestatic pruritus in ALGS/PFIC [1] - Haierisi (injectable idursulfase beta) for treating Mucopolysaccharidosis Type II [1]